PD-1 inhibition with retifanlimab and/or arginase inhibition with INCB001158 in Japanese patients with solid tumors: A phase I study.
Yasutoshi KubokiTakafumi KoyamaNobuaki MatsubaraYoichi NaitoShunsuke KondoKenichi HaranoKan YonemoriKiyotaka YohYuan GuTetsuya MitaXuejun ChenEiji UedaNoboru YamamotoToshihiko DoiToshio ShimizuPublished in: Cancer medicine (2024)
Retifanlimab, INCB001158, and their combination had acceptable safety profiles. Promising retifanlimab antitumor activity warrants further investigation in Japanese patients.
Keyphrases